Q3 EPS Forecast for Nurix Therapeutics Lowered by Analyst

Nurix Therapeutics, Inc. (NASDAQ:NRIX) – Investment analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Nurix Therapeutics in a research report issued to clients and investors on Friday, July 10th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.69) for the quarter, down from their prior estimate of ($0.68). HC Wainwright has a “Buy” rating and a $34.00 price target on the stock. The consensus estimate for Nurix Therapeutics’ current full-year earnings is ($2.88) per share. HC Wainwright also issued estimates for Nurix Therapeutics’ Q4 2026 earnings at ($0.63) EPS and FY2026 earnings at ($2.91) EPS.

Several other research analysts have also commented on NRIX. Stifel Nicolaus raised their price objective on Nurix Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research report on Friday. BTIG Research reiterated a “buy” rating and set a $32.00 target price on shares of Nurix Therapeutics in a report on Friday. Wall Street Zen raised Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. Robert W. Baird upped their price target on Nurix Therapeutics from $26.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, June 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $34.08.

Nurix Therapeutics Trading Down 1.5%

Shares of NRIX stock opened at $22.71 on Tuesday. The company has a market cap of $2.36 billion, a PE ratio of -6.58 and a beta of 1.80. The company’s fifty day simple moving average is $18.56 and its 200-day simple moving average is $17.38. Nurix Therapeutics has a 52 week low of $8.19 and a 52 week high of $25.08.

Nurix Therapeutics (NASDAQ:NRIX) last released its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The firm had revenue of $9.04 million during the quarter, compared to analyst estimates of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 14,055 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $16.60, for a total value of $233,313.00. Following the transaction, the chief financial officer directly owned 37,592 shares of the company’s stock, valued at $624,027.20. This represents a 27.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total value of $107,880.00. Following the transaction, the insider owned 115,005 shares of the company’s stock, valued at approximately $2,300,100. This trade represents a 4.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,051 shares of company stock worth $434,466 over the last 90 days. 6.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Institutional investors have recently modified their holdings of the stock. General Atlantic L.P. acquired a new stake in Nurix Therapeutics during the fourth quarter valued at approximately $92,899,000. Vanguard Group Inc. grew its position in shares of Nurix Therapeutics by 32.5% in the 4th quarter. Vanguard Group Inc. now owns 5,949,512 shares of the company’s stock worth $112,862,000 after acquiring an additional 1,460,736 shares in the last quarter. Baker BROS. Advisors LP grew its position in shares of Nurix Therapeutics by 20.0% in the 4th quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock worth $88,373,000 after acquiring an additional 776,431 shares in the last quarter. Flax Pond Capital LLC bought a new stake in shares of Nurix Therapeutics in the 4th quarter valued at approximately $1,521,000. Finally, Perceptive Advisors LLC increased its holdings in shares of Nurix Therapeutics by 151.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,555,877 shares of the company’s stock valued at $67,455,000 after acquiring an additional 2,139,728 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.